[Myalgic encephalomyelitis/chronic fatigue syndrome as a complication of COVID-19 post-acute syndrome in adults. Bibliographic Review].
Carrillo Uguña, Miguel Esteban, Orellana Romero, Paula Michelle · Vertex (Buenos Aires, Argentina) · 2024 · DOI
Quick Summary
This review examines how some COVID-19 survivors develop symptoms very similar to ME/CFS weeks or months after their acute infection ends. The authors found that over 87% of COVID-19 patients still experience at least one symptom two months after infection, and some of these symptoms match what ME/CFS patients experience. The study suggests that COVID-19 may trigger ME/CFS-like illness in some adults, similar to how other infections have been linked to ME/CFS in the past.
Why It Matters
This review is important because it formally documents the emerging clinical observation that COVID-19 may precipitate ME/CFS-like illness in some survivors, which helps validate patients' experiences and may prompt clinicians to recognize post-COVID ME/CFS cases. Understanding this potential link could improve diagnosis and management of a significant post-pandemic complication affecting millions of people worldwide.
Observed Findings
Over 87% of COVID-19 patients continue experiencing at least one symptom two months after infection onset
Post-acute COVID-19 patient reports and early observational studies describe syndromes clinically similar to ME/CFS
ME/CFS has been associated with other viral infections in the general population
ME/CFS prevalence in the general population ranges from 0.17-0.89% and is more common in females
Post-COVID sequelae have been reported globally in multiple patient cohorts persisting months after hospital discharge
Inferred Conclusions
ME/CFS may constitute a complication of post-acute COVID-19 syndrome in some adult survivors
COVID-19 shares characteristics with other infections previously linked to ME/CFS development
The multisystem, chronic nature of post-acute COVID-19 symptoms overlaps significantly with ME/CFS clinical presentation
Identifying ME/CFS as a post-COVID complication is clinically relevant for patient management and recognition
Remaining Questions
What is the precise incidence and prevalence of ME/CFS specifically among COVID-19 survivors?
What This Study Does Not Prove
This review does not establish causal mechanisms linking COVID-19 infection to ME/CFS development, nor does it provide precise incidence rates of ME/CFS among COVID-19 survivors. The study cannot distinguish between symptom overlap and true ME/CFS diagnosis, and cannot rule out alternative explanations for persistent symptoms in post-COVID patients.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →